Iron Levels in Polycythemia Vera After Therapeutic Phlebotomy
Patients with polycythemia vera typically present with iron deficiency at diagnosis and develop progressively worsening iron depletion during therapeutic phlebotomy, characterized by low serum ferritin, low serum iron, and persistently elevated transferrin saturation until iron stores are completely depleted.
Baseline Iron Status in Polycythemia Vera
Virtually all PV patients are iron deficient at presentation or during their disease course 1. This creates a physiological paradox—the coexistence of iron deficiency with polycythemia 1. The iron deficiency occurs due to:
- Increased erythropoiesis consuming available iron stores
- Dysregulated iron metabolism inherent to the disease pathophysiology
- Insufficiently suppressed hepcidin levels despite iron deficiency 1
Iron Panel Changes During Therapeutic Phlebotomy
During the phlebotomy induction phase, iron parameters follow a predictable pattern:
- Serum iron: Declines significantly from baseline (mean decline from 132.85 μg/dL to 69.41 μg/dL) 2
- Transferrin saturation (TS): Remains elevated until iron stores are depleted, then drops 3
- Serum ferritin: Initially fluctuates, then progressively falls with iron mobilization 3
- Red cell ferritin: Significantly reduced compared to normal individuals 4
Target Iron Levels and Monitoring
The evidence shows that iron deficiency should be avoided, not induced 3. However, the practical reality is that therapeutic phlebotomy inevitably causes progressive iron depletion:
- Each phlebotomy removes approximately 200-250 mg of iron 3
- Patients requiring frequent phlebotomy to maintain hematocrit <45% will develop worsening iron deficiency 5, 6
- The goal is hematocrit control, not iron depletion—but iron depletion is an unavoidable consequence
Clinical Consequences of Iron Deficiency
Iron deficiency in PV patients produces significant symptoms that diminish quality of life 5, 7:
- Fatigue and lethargy
- Impaired concentration and cognitive dysfunction
- Headaches and dizziness
- Inactivity
Important caveat: These symptoms overlap substantially with PV disease symptoms, making it difficult to distinguish iron deficiency symptoms from disease-related symptoms in clinical practice.
Key Differences from Hemochromatosis
The provided evidence about hemochromatosis (targeting ferritin 50-100 μg/L) 3 is not applicable to PV patients. In hemochromatosis, iron depletion is therapeutic; in PV, iron deficiency is an unwanted consequence of necessary hematocrit control.
Practical Monitoring Approach
For PV patients undergoing therapeutic phlebotomy:
- Before each phlebotomy: Check hemoglobin/hematocrit
- Periodically: Monitor complete iron panel (serum iron, ferritin, transferrin saturation)
- Watch for: Hemoglobin <12 g/dL (reduce phlebotomy frequency) or <11 g/dL (discontinue phlebotomy) 8
The iron deficiency will worsen with continued phlebotomy, but this must be balanced against the critical need to maintain hematocrit <45% to prevent thrombosis 6. Cytoreductive therapy (hydroxyurea, interferon, or ruxolitinib) can reduce phlebotomy requirements and allow some iron recovery 7, 6.